Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Bases de dados
Tipo de documento
Assunto da revista
País de afiliação
Intervalo de ano de publicação
1.
Retrovirology ; 7: 1, 2010 Jan 15.
Artigo em Inglês | MEDLINE | ID: mdl-20078884

RESUMO

BACKGROUND: The human immunodeficiency virus type 1 (HIV-1) Vpu protein degrades CD4 and counteracts a restriction factor termed tetherin (CD317; Bst-2) to enhance virion release. It has been suggested that both functions can be genetically separated by mutation of a serine residue at position 52. However, recent data suggest that the S52 phosphorylation site is also important for the ability of Vpu to counteract tetherin. To clarify this issue, we performed a comprehensive analysis of HIV-1 with a mutated casein kinase-II phosphorylation site in Vpu in various cell lines, primary blood lymphocytes (PBL), monocyte-derived macrophages (MDM) and ex vivo human lymphoid tissue (HLT). RESULTS: We show that mutation of serine 52 to alanine (S52A) entirely disrupts Vpu-mediated degradation of CD4 and strongly impairs its ability to antagonize tetherin. Furthermore, casein-kinase II inhibitors blocked the ability of Vpu to degrade tetherin. Overall, Vpu S52A could only overcome low levels of tetherin, and its activity decreased in a manner dependent on the amount of transiently or endogenously expressed tetherin. As a consequence, the S52A Vpu mutant virus was unable to replicate in macrophages, which express high levels of this restriction factor. In contrast, HIV-1 Vpu S52A caused CD4+ T-cell depletion and spread efficiently in ex vivo human lymphoid tissue and PBL, most likely because these cells express comparably low levels of tetherin. CONCLUSION: Our data explain why the effect of the S52A mutation in Vpu on virus release is cell-type dependent and suggest that a reduced ability of Vpu to counteract tetherin impairs HIV-1 replication in macrophages, but not in tissue CD4+ T cells.


Assuntos
HIV-1/fisiologia , Proteínas do Vírus da Imunodeficiência Humana/fisiologia , Macrófagos/virologia , Glicoproteínas de Membrana/antagonistas & inibidores , Linfócitos T/virologia , Proteínas Virais Reguladoras e Acessórias/fisiologia , Liberação de Vírus , Replicação Viral , Substituição de Aminoácidos , Antígenos CD , Antígenos CD4/metabolismo , Linhagem Celular , Células Cultivadas , Proteínas Ligadas por GPI , Proteínas do Vírus da Imunodeficiência Humana/genética , Humanos , Mutagênese Sítio-Dirigida , Proteínas Mutantes/genética , Proteínas Mutantes/fisiologia , Proteínas Virais Reguladoras e Acessórias/genética
2.
J Gen Virol ; 89(Pt 12): 3016-3026, 2008 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-19008388

RESUMO

The e antigen (eAg) of duck hepatitis B virus (DHBV) is a glycosylated secretory protein with a currently unknown function. We concentrated this antigen from the supernatants of persistently infected primary duck liver cell cultures by ammonium sulphate precipitation, adsorption chromatography over concanavalin A Sepharose, preparative isoelectric focusing and molecular sieve chromatography. The combined treatment of duck liver cells with DHBV eAg (DHBe) concentrate and alpha-methyl-d-mannopyranoside strongly inhibited DHBV replication at de novo infection. When DHBe was added to non-infected primary duck liver cells, it was found to be associated with liver sinusoidal endothelial cells. This binding could be inhibited by the addition of alpha-methyl-d-mannopyranoside and other sugar molecules. The inhibitory effect of DHBe on infection could play a role in maintaining viral persistence.


Assuntos
Vírus da Hepatite B do Pato/efeitos dos fármacos , Vírus da Hepatite B do Pato/patogenicidade , Antígenos E da Hepatite B/farmacologia , Hepatócitos/virologia , Metilmanosídeos/farmacologia , Replicação Viral/efeitos dos fármacos , Animais , Carboidratos/farmacologia , Células Cultivadas , Patos , Infecções por Hepadnaviridae/virologia , Vírus da Hepatite B do Pato/fisiologia , Antígenos E da Hepatite B/isolamento & purificação , Antígenos E da Hepatite B/metabolismo , Hepatite Viral Animal/virologia , Fígado/citologia , Fígado/virologia
3.
J Virol ; 81(10): 5014-23, 2007 May.
Artigo em Inglês | MEDLINE | ID: mdl-17360753

RESUMO

Hepatitis B viruses exhibit a narrow host range specificity that is believed to be mediated by a domain of the large surface protein, designated L. For duck hepatitis B virus, it has been shown that the pre-S domain of L binds to carboxypeptidase D, a cellular receptor present in many species on a wide variety of cell types. Nonetheless, only hepatocytes become infected. It has remained vague which viral features determine host range specificity and organotropicity. By using chymotrypsin to treat duck hepatitis B virus, we addressed the question of whether a putative fusogenic region within the amino-terminal end of the small surface protein may participate in viral entry and possibly constitute one of the determinants of the host range of the virus. Addition of the enzyme to virions resulted in increased infectivity. Remarkably, even remnants of enzyme-treated subviral particles proved to be inhibitory to infection. A noninfectious deletion mutant devoid of the binding region for carboxypeptidase D could be rendered infectious for primary duck hepatocytes by treatment with chymotrypsin. Although because of the protease treatment mutant and wild-type viruses may have become infectious in an unspecific and receptor-independent manner, their host range specificity was not affected, as shown by the inability of the virus to replicate in different hepatoma cell lines, as well as primary chicken hepatocytes. Instead, the organotropicity of the virus could be reduced, which was demonstrated by infection of primary duck kidney cells.


Assuntos
Vírus da Hepatite B do Pato/fisiologia , Hepatócitos/virologia , Rim/virologia , Proteínas do Envelope Viral/fisiologia , Proteínas Virais de Fusão/fisiologia , Internalização do Vírus , Animais , Linhagem Celular , Células Cultivadas , Galinhas , Quimotripsina/metabolismo , Patos , Vírus da Hepatite B do Pato/genética , Rim/citologia , Estrutura Terciária de Proteína , Proteínas do Envelope Viral/genética , Proteínas Virais de Fusão/genética
4.
Hepatology ; 38(5): 1274-81, 2003 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-14578867

RESUMO

Hepatitis B virus with a G145R mutation in the small surface protein is considered the quintessential immune escape mutant because it frequently is found in vaccinated individuals with breakthrough infections and liver transplant recipients under anti-hepatitis B surface antigen (HBsAg) immunoglobulin prophylaxis. Nowadays the prevalence of the variant progressively increases. However, because spread of a virus depends not only on immune pressure but also on the viral phenotype, we investigated the biologic properties of the G145R variant. The G145R mutation was introduced into wild-type (Wt) virus genome by in vitro mutagenesis. After transfection into human hepatoma cells, the DNA, RNA, and protein synthesis and viral secretion ability of the mutant were studied. Furthermore, cotransfection studies were performed with the G145R variant and a Wt virus S-protein expressing construct and vice versa. Production and stability of viral messenger RNAs (mRNAs), DNA, and proteins were not affected by the G145R mutation. In contrast, secretion of mutant virions was reduced significantly. Only 20% of virions were found in the medium of G145R variant-transfected cells compared with Wt virus. Furthermore, mutant virions were more sensitive to detergent treatment suggesting a diminished stability. In cotransfection studies, Wt virus S-protein rescued secretion of mutant virions, whereas mutant S-protein had a transdominant negative effect on secretion of Wt virus. Both mechanisms may support persistence of the defective mutant in a mixed population with Wt virus. In conclusion, the significant defect of the G145R mutant for secretion of infectious virions and the diminished stability of mutant virions may limit global spread of the mutant.


Assuntos
Vírus da Hepatite B/genética , Vírus da Hepatite B/metabolismo , Mutação , Vírion/metabolismo , Linhagem Celular Tumoral , Fenômenos Químicos , Físico-Química , Meios de Cultura/metabolismo , DNA Viral/metabolismo , Detergentes/farmacologia , Genoma Viral , Homeostase , Humanos , Mutagênese Insercional , Mutação/fisiologia , Octoxinol , Polietilenoglicóis/farmacologia , RNA Mensageiro/metabolismo , RNA Viral/metabolismo , Transfecção , Proteínas Virais/metabolismo , Vírion/química , Vírion/efeitos dos fármacos , Replicação Viral
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA